ClinicalTrials.gg
RecruitingNCT05937477Updated Jul 21, 2023

Developing Artificial Intelligence-based Algorism to Predict Side Effects and Symptoms From Chemotherapy

An observational study in Lung Cancer, Head and Neck Cancer and Esophageal Cancer, sponsored by Sehhoon Park. Recruiting at 1 site in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2023-07-21.

Sponsored by Sehhoon Park · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
500
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 246 studies in Lung Neoplasms with a site in Korea, Republic of — 52 open to participants now, 81 under way, 26 of them phase 3. Lung Neoplasms · Korea, Republic of.

Planned enrollment
12th of 44
500 · median 151
Started
2023
with 10 others
Observational
44 of 246
11 open now
Primary completion
2025-12
later than 11 of 80 live
Registered
191st of 246
by date

Among the 246 studies in Lung Neoplasms with a site in Korea, Republic of, this one is the 12th largest by planned enrollment of the 44 observational ones that give a count, is one of 11 that started in 2023, is one of 44 observational ones, reaches primary completion later than 11 of the 80 other live ones, and was the 191st registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

52 of the 246 studies in Lung Neoplasms with a site in Korea, Republic of are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 246 studies in Lung Neoplasms with a site in Korea, Republic of, or all of them as a file.
02

Study summary

In this study, the investigators obtain wearable disease based biomarkers from patients diagnosed with cancer and undergoing chemotherapy, and simultaneously measure patient self-reported adverse events through an app to evaluate chemotherapy completion rates, emergency room visits, and frequency of CTCAE adverse events.

The investigators will develop an artificial intelligence-based algorism that can predict patients' side effects based on biomarkers alone.

Read the detailed description

In this study, patients diagnosed with lung, head and neck, and esophageal cancers and undergoing chemotherapy will be measured for self-reported side effects using a wearable device to collect biomarkers through an app, and the association between patient quality of life and side effects and biomarkers obtained from the wearable device will be analyzed. On the other hand, blood (EDTA 3cc) for pharmacogenomics testing will be tested once at any point during the study period as an indicator associated with side effects after chemotherapy.

03

Conditions studied

  • Lung Cancer
  • Head and Neck Cancer
  • Esophageal Cancer
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients undergoing chemotherapy after being diagnosed with lung, head and neck, or esophageal cancer.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 20 years of age or older
  • Must have diagnosed with lung, head and neck, or esophageal cancer,

    1. scheduled to receive their first treatment in preoperative or postoperative chemotherapy.
    2. scheduled for systemic chemotherapy due to recurrence or .
  • Eastern Cooperative Oncology () performance status of 0 to 2.
  • Patients who have access to a smartphone and can use the mobile app on their own.
  • Understand the purpose of the study and agree to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Patients who, in the judgment of the researcher, have difficulty using the application.
  • Patients who are judged by the medical staff to be unable to participate in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • Neoadjuvant, Adjuvant Chemotherapy Arm

    Patients diagnosed with lung, head and neck, or esophageal cancer and undergoing Neoadjuvant, Adjuvant chemotherapy.

    Other: Fitbit smartwatch

  • Palliative Chemotherapy Arm

    Patients diagnosed with lung, head and neck, or esophageal cancer and undergoing Palliative chemotherapy.

    Other: Fitbit smartwatch

Interventions

  • OtherFitbit smartwatch

    Patients wear the wearable to check their biomarkers and use the application to assess their quality of life and side effects at one-week intervals.

06

What researchers measure

Primary outcomes

  1. Developing artificial intelligence prediction algorism

    PRO data and treatment information collected from the wearable are used to evaluate correlations through methods such as linear regression to determine valid variables, utilizing LSTM models, etc.

    Time frame: Through study completion, an average of 30 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Dec 2025, 30 months after the start.

Of 592 non-industry observational studies under Lung Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 162. This study's planned 30 months is below that.

Counting every sponsor, half of 682 studies reached it within 57 months; a quarter within 25 and three quarters within 135.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2023
First posted
Jul 10, 2023
StartActual
Jun 8, 2023
Primary completionEst.
Dec 31, 2025
CompletionEst.
Jun 30, 2026
Last update
Jul 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05937477
Lead sponsor
Sehhoon Park
Responsible party
Sehhoon Park (M.D, Ph.D. Principal Investigator, Clinical Professor, Samsung Medical Center) — Sponsor-investigator
First posted
Jul 10, 2023
Start date
Jun 8, 2023
Primary completion
Dec 31, 2025 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Jul 21, 2023

Study contacts

Sehhoon Park, MD
Contact
sehhoon.park@samsung.com
+82-10-9185-8619

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion